AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
RegulatorypositiveTelisotuzumab AdizutecanPositive
AI Analysis
Summary
AbbVie announced that telisotuzumab adizutecan (Temab-A/ABBV-400) has received two Breakthrough Therapy Designations from the FDA for colorectal cancer and non-small cell lung cancer, recognizing the drug's potential to address serious conditions with preliminary evidence of substantial improvement.
Outcome Details
Two Breakthrough Therapy Designations granted by FDA
Importance:8/10
Sentiment:
0.85
Breakthrough Therapy DesignationFDAOncologyTelisotuzumab AdizutecanCRCNSCLC
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 7, 2026 11:10 PM